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ABSTRACT:
Current therapeutic regimens attempt to eliminate all malignant cells of a melanoma 
lesion. Pre-clinical data, however, indicate that melanoma is maintained by a minor 
subset of cancer cells, which are characterized by CD20 expression. We attempted 
to eliminate those cells in a progressing, chemotherapy-refractory metastatic 
melanoma patient by lesional injections of the anti-CD20 therapeutic antibody 
rituximab and concomitant dacarbazine treatment, which was ineffective as 
monotherapy. Although the frequency of CD20+ melanoma cells within the tumor 
lesions was initially about 2% and the bulk of tumor cells did not express CD20, 
rituximab treatment produced lasting remission accompanied by a decline of the 
melanoma serum marker S-100 to physiological levels. Detailed in-depth-analyses 
revealed a switch of serum cytokines from a T helper-2 to a pro-inflammatory T 
helper-1 cell profile. Apart from B cell elimination and decline in gammaglobulin 
levels, no grade 3/4 toxicity related to treatment was observed. Data provide 
the first clinical evidence that targeting the minor subset of CD20+ “melanoma 
sustaining cells” produces regression of chemotherapy-refractory melanoma and 
highlight the potency of selective cancer cell targeting in the treatment of melanoma.
INTRODUCTION
Current regimens in cancer therapy attempt to 
eliminate all malignant cells of a tumor lesion; the 
approach is based on the assumption that every cancer 
cell has equal malignant capacities. The contrary paradigm 
that an established tumor lesion is hierarchically organized 
is supported by the enormous cellular heterogeneity of 
tumor lesions with a minority of tumor cells, but not a 
random cancer cell, which populates the tumor cell mass, 
initiates tumor growth and drives progression [1]. Cancer 
initiating cells renew themselves, are more resistant to 
chemo- and radiotherapy, stay quiescent for long time, 
and drift to distant sites to initiate metastases and relapse 
after treatment [2]. For instance, metastatic relapse of 
melanoma can occur more than a decade after curative 
surgical treatment of the primary lesion; this phenomenon 
is thought to be due to the same cancer initiating cell that 
drives cancer progression.
Although cancer stem cells have been experimentally 
proven for a variety of solid tumors and leukemia by 
their functional capacities, they do not share a common 
marker.  In  the  melanoma  CD20  was  first  reported  to 
be expressed on those cells [3]; other reports showed 
ABCB5 [4], CD271 [5] and other markers depending on 
the assay used to test for cancer stem capacities. These 
tumor-initiating cells may be variable in number and must 
not necessarily be rare in the case of melanomas [6,7]. Oncotarget 2012; 3:  22 - 30 23 www.impactjournals.com/oncotarget
Moreover, melanoma cells exhibit a remarkable plasticity 
since isolated melanoma cells of different phenotypes can 
initiate new tumor lesions by asymmetric cell divisions 
when transplanted under appropriate conditions. Once 
established, however, a minor subset of melanoma cells 
seems to maintain tumor progression. A major implication 
thereof  is  that  specific  elimination  of  the  minor  side 
population with tumor progression capacities may be 
sufficient  to  shrink  the  tumor  in  the  long  term.  The 
assumption is sustained by mathematical models implying 
that successful tumor therapy requires eradication of those 
stem cells to produce complete clinical response [8]. A 
strong rationale for selective cancer cell elimination in 
melanoma therapy was most recently provided by the 
observation that targeted elimination of the less than 2% 
subset of CD20+ melanoma cells in a transplantation model 
can lastingly eradicate the tumor lesion [9,10]. While 
those pre-clinical data imply CD20+ melanoma cells as 
the major driver of melanoma progression, we here firstly 
report complete remission of melanoma upon targeting of 
the CD20+ subset of melanoma cells by the CD20-specific 
therapeutic antibody rituximab in off-label use in a patient 
with advanced metastatic melanoma.
RESULTS
Case Report
The patient, a 74-aged Caucasian male, received 
a diagnosis of stage IIIB (AJCC) ulcerated, acro-
lentiginous malignant melanoma on the left heel with a 
tumor thickness of 2.0 mm in May 2010. Surgical tumor 
excision was conducted with a 3 cm margin. Inguinal 
lymph nodes were infiltrated with tumor cells, whereas 
popliteal lymph nodes were found to be free of tumor 
cells by lymph node scintigraphy and sentinel lymph node 
biopsy. Tumor cells exhibited wild-type alleles of BRAF 
and c-Kit as revealed by RT-PCR. The patient received 
adjuvant therapy with interferon-alpha (3 mio. IU s.c. 
three times a week) from August to October 2010. Left 
inguinal lymphadenopathy enforced lymphadenectomy 
in November 2010 with extirpation of 5 lymph nodes; 
three of them with metastatic infiltrations, one of which 
extended beyond the lymph node capsule. In February 
2011, the patient progressed into AJCC stage IV (M1a) 
day -82 day -62 day -28 day -12 day 1
target lesion target lesion
p.m. i.l.n.m. p.m. i.l.n.m.
treatment 
rituximab in plantar lesion 2x10 mg
rituximab in popliteal lesion 3x10 mg
rituximab in inguinal lesion 
dacarbazine 1g/m
2 1g/m
2
biopsy plantar lesion
CT and MRI scans n.a. 15 mm 4.7x2 cm 19 mm
day 7 day 15 day 20 day 29 day 36     day 48 day80
target lesion RECIST
p.m. i.l.n.m.
treatment 
rituximab in plantar lesion 1x10 mg 1x10 mg 1x10 mg 1x10 mg 1x40 mg 1x40 mg
rituximab in popliteal lesion 2x10 mg 2x10 mg 2x10 mg 2x10 mg 2x40 mg 2x40 mg
rituximab in inguinal lesion  1x10 mg 2x10 mg 2x10 mg 2x10 mg 2x40 mg 2x40 mg
dacarbazine 1 g/m
2 1 g/m
2
biopsy plantar lesion 
CT and MRI scans 1.3x1.1 cm 1.2 cm PR
day 101 day 129 day 187 day 194 day 228
target lesion RECIST
p.m. i.l.n.m.
treatment 
rituximab i.v.  187.5mg/m² 375mg/m²
rituximab in plantar lesion
rituximab in popliteal lesion
rituximab in inguinal lesion 2x40 mg 2x40 mg
dacarbazine 1 g/m
2 1 g/m
2
biopsy surgery
CT and MRI scans CR 0.9 cm PR
p.m., popliteal metastasis; i.l.n.m., inguinal lymph node metastasis; n.a., not applied; PR, partial remission; CR, complete remission.
Table 1: Treatment schedule of melanoma lesions.Oncotarget 2012; 3:  22 - 30 24 www.impactjournals.com/oncotarget
with disseminated lymph node metastases and multiple 
widespread cutaneous and subcutaneous metastases. The 
patient’s skin and lymph node metastases still progressed 
during two further cycles of therapy with dacarbazine 
(1 g/m2 every 4 weeks) combined with epifocal 
dinitrochlorobenzene (DNCB) treatment in increasing 
doses from 0.1% up to 2% once per week accordingly 
to Trcka et al [11]. The patient did not meet inclusion 
criteria of ongoing trials. In May 2011, the patient was 
enrolled in an off-label use of rituximab according to the 
treatment schedule Table 1. The procedure was reviewed 
and approved by the institutional “Tumor Review Board 
of the Center for Integrated Oncology (CIO)”, University 
Hospital of Cologne.
Therapeutic anti-CD20 antibody injections
A cutaneous melanoma lesion from the left heel was 
subjected to immunohistological screening for CD20+ 
melanoma cells. As shown in Fig. 1, a minority of cells in 
the melanoma lesion expressed CD20 which represented 
about 2% of melanoma cells. The patient was subjected to 
off-label therapy with intra-lesional rituximab injections 
after informed consent. Treatment started with rituximab 
injections at a total dose of 20 mg into a cutaneous 
metastasis at the left heel and 30 mg into metastases in the 
popliteal region (for treatment schedule see Table 1). Since 
no toxicity was observed, the same lesions were treated 
again at day 7 together with an additional inguinal lesion, 
each lesion with a total dose of 10 – 20 mg rituximab. 
The same procedure was repeated at day 15, 20 and 29. At 
day 36, injected dose of rituximab was increased to 40 - 
80 mg per lesion and repeated 12 days later. The ongoing 
treatment with dacarbazine (1 g/m2) every four weeks 
was continued and administered on days 20 and 48. Aside 
from minimal swelling due to the injection volume, no 
local or systemic toxicity was observed. Rituximab was 
administered by i.v. injection in a dose of 187.5 mg/m² at 
day 101 and in a dose of 375 mg/m² at day 129 followed 
by local injections into the inguinal lesion at day 187 and 
day 194. The remaining inguinal lesion was removed by 
surgery at day 228.
Clinical response and evaluations
Cutaneous melanoma lesions and metastases 
continuously progressed during treatment with 
dacarbazine and DNCB. After 7 courses of rituximab 
injections, however, treated metastases had substantially 
regressed or were no longer detectable (Table 1). 
Histological screening of a treated lesion in far distance 
from the first biopsy confirmed morphological destruction 
of the melanoma tissue; no CD20+ melanoma cells were 
detected (Fig. 1). Interestingly, no substantial infiltration 
by immune cells occurred during treatment. Sonographic 
recording  confirmed  continuous  regression  of  a  left 
popliteal metastasis from approximately 38 x 19 mm to 
15 x 9 mm in diameter within the course of 7 rituximab 
Figure 1: Rituximab treatment reduced the number of CD20+ melanoma cells in treated metastases. Metastatic melanoma 
lesions harbor CD20+ melanoma cells. Cryostat sections of a cutaneous metastatic melanoma lesion prior and after rituximab treatment were 
stained for CD20 and visualized by peroxidase-AEC reaction. The biopsy after rituximab treatment was taken from the same melanoma 
lesion but distant from first biopsy. Staining with an isotype matched antibody of irrelevant specificity served as control. Hematoxylin-
eosin (H&E) staining shows the histology. Of note, rituximab binding does not interfere with staining by the anti-CD20 antibody used in 
this analysis.
20µm  20µm  20µm 
CD20  isotype control 
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after rituximab treatment 
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treatments (Fig. 2). Regression of melanoma lesions 
was furthermore objectified by MRI scan as exemplarily 
shown in Fig. 3. Both popliteal metastases regressed 
during treatment and complete remission was achieved 
within 7 months of rituximab therapy. Although they 
had not received intra-tumoral injections, the inguinal 
metastasis regressed during therapy as well (Fig. 4). While 
the metastasis progressed during chemotherapy from 15 
mm to 19 mm in diameter within 3 months, they regressed 
to 9 mm as revealed by CT scans and was removed by 
surgery 7 months after first rituximab treatment (Fig. 4). 
Along with the regression of metastatic melanoma 
lesions, serum S-100, a marker for melanoma progression, 
declined during rituximab therapy from 1.78 µg/l to 
near physiological levels (0.23 - 0.11 µg/l)  (Fig. 5). 
Other serum enzymes including LDH and AP were in 
the physiological range. Recording of peripheral blood 
immune cells revealed complete depletion of CD19+ B 
cells, accompanied by decline in gamma-globulin levels, 
which was most likely due to rituximab targeting healthy 
B cells. CD4:CD8 T cell ratio was increased with increase 
in CD4+ helper T cells to 81% and decrease in effector 
CD8+ T cells to 7%. Before rituximab treatment the panel 
of serum cytokines indicated a predominant TH2 immune 
status which changed to a more pro-inflammatory TH1 
cytokine signature at day 82 after rituximab treatment 
indicated  by  increase  in  IFN-γ,  TNF-α,  and  other 
cytokines including IL-12 (Table 2). The elevated number 
of CD4+ helper T cells was accompanied by increased 
serum levels of IL-1β, IL-9, IL-10 and eotaxin pointing 
on their increased functional activity. The anti-angiogenic 
factor CXCL10 was additionally increased after rituximab 
treatment which together with a decreased VEGF level 
likely contributes to the shrinkage of the melanoma 
lesions.  
DISCUSSION
We report that local treatment with the therapeutic 
anti-CD20 antibody rituximab produced complete 
regression of all melanoma metastases with the exception 
before rituximab treatment  after 7 courses  rituximab 
treatment  
after 9 courses  rituximab 
treatment 
Figure 2: Sonographic recording of the popliteal left metastasis during rituximab therapy. The metastasis substantially 
shrinks during therapy from approximately 722 mm2 to 135 mm2, i.e., a reduction by 80%; note that the blood vessel immediately under 
the metastasis showed nearly the same diameter in these projections. 
4.7x2 cm  1.3x1.1 cm 
before rituximab treatment  after 7 courses rituximab treatment  after  9 courses rituximab treatment 
Figure 3: Complete regression of the metastases in the left popliteal region during rituximab therapy. Popliteal metastases 
were screened by MRI before the start of rituximab treatment (day -28) and after 7 and 9 courses of local treatment. The popliteal bulk of 
metastases measured 4.7 x 2 cm before therapy and regressed to 1.3 x 1.1 cm and disappeared after 9 courses of treatment (right arrow). 
Left arrow indicates a solitary metastasis which completely disappeared after 7 courses. Complete remission was stable.Oncotarget 2012; 3:  22 - 30 26 www.impactjournals.com/oncotarget
Cytokine day –28 [pg/ml]1 day 82 [pg/ml]1 change
IL-1b <1.91 20.82 ± 7.78 +++
IL-1RA 314.04 ± 11.67 772.17 ± 6.36 ++
IL-2 <1.03 <1.03 o
IL-4 5.17 ± 9.90 31.09 ± 18.74 +
IL-5 <1.82 <1.82 o
IL-6 37.58 ± 28.64 18.84 ± 3.54 o
IL-7 16.47 ± 7.07 15.43 ± 2.83 o
IL-8 28.43 ± 26.16 18.29 ± 3.18 o
IL-9 23.94 ± 3.18 71.08 ± 2.41 ++
IL-10 <1.53 30.19 ± 22.63 ++
IL-12(p70) 31.97 ± 9.90 99.51 ± 9.19 ++
IL-13 <2.22 21.77 ± 1.77 +++
IL-15 <1.69 <1.69 o
IL-17 15.85 ± 4.95 13.65 ± 2.83 o
Eotaxin <6.51 85.27 ± 5.30 +++
bFGF 24.08 ± 7.42 25.41 ± 0.71 o
G-CSF 57.64 ± 3.18 120.95 ± 1.06 ++
GM-CSF 43.31 ± 54.45 130.24 ± 12.73 ++
IFN-g 175.83 ± 11.31 1000.62 ± 19.09 +++
CXCL10 635.84 ± 172.89 1787.78 ± 8.49 ++
CCL2 32.78 ± 62.93 85.83 ± 10.61 o
CCL3 11.96 ± 20.15 16.71 ± 0.71 o
CCL4 129.09 ± 250.32 217.72 ± 14.14 o
PDGF-bb 8051.16 ± 873.28 6977.90 ± 57.28 -
TNF-a <19.18 153.91 ± 8.49 +++
VEGF 144.04 ± 47.73 87.91 ± 1.77 -
1mean +/- SD; < below detection level; 
+ increase < 2fold; ++ increase ≥ 2fold; +++ increase ≥ 5fold; 
- decrease < 2fold; - - decrease ≥ 2fold; - - - decrease ≥ 5fold;
o no significant change
15 mm  19 mm 
12 mm 
before treatment  progress  
after dacarbazine + DNCB 
treatment 
regression 
after 7 courses rituximab  
treatment  
9 mm 
regression 
after 9 courses rituximab  
treatment 
Figure 4: Partial regression of the inguinal metastasis during rituximab therapy. CT scans of the inguinal region before the 
start of any treatment (day -82), dacarbazine plus DNCB treatment (day -12), and after 7 and 9 courses of rituximab injections. The inguinal 
metastasis progressed during chemotherapy from 15 mm to 19 mm in diameter; rituximab treatment produced substantially regression to 
12 mm after 7 courses and to 9 mm after 9 courses of treatment, i.e., within 24 weeks. The solitary metastasis was stable and removed by 
surgery.
Table 2: Serum cytokine profile before and after rituximab treatment.Oncotarget 2012; 3:  22 - 30 27 www.impactjournals.com/oncotarget
of one lesion which showed partial but stable regression. 
The observation is unexpected since the melanoma 
metastases were continuously progressing during 
chemotherapy while rituximab therapy targeted CD20+ 
melanoma cells which comprised about 2% of cells in 
the lesions whereas the majority of melanoma cells lack 
CD20. After the elimination of CD20+ melanoma cells, 
notably, the number of CD20- melanoma cells declined 
accompanied by a decrease in the S-100 serum marker to 
near physiological levels. 
It was unexpected that the very low doses of 
lesionally applied rituximab would result in clinically 
evident tumor regression. Indeed, the injected doses 
of 10 - 40 mg rituximab per lesion once a week were 
several orders of magnitude below doses used in current 
lymphoma therapy in which rituximab is systemically 
administered [12]. Subcutaneous drug injections, almost 
produce some systemic leachate, even when the drug 
is administered at low doses, which explains tumor 
shrinkage at remote sites. The conclusion is sustained by 
the fact that locally injected rituximab was sufficient to 
clear healthy CD20+ B cells from the peripheral blood 
circulation in long-term as indicated by flow cytometric 
decline in B cell counts and the gradual decline in serum 
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Figure 5: Laboratory parameters. Serum and blood cell parameters were determined 6 weeks before and after 6 weeks of rituximab 
treatment. Serum melanoma marker S-100 and the enzymes lactate dehydrogenase (LDH) and alkaline phosphatase (AP) as well as the 
serum immunoglobulin-G (IgG) subsets were determined. The respective lymphocyte subsets of B cells (CD19+) and of T cells (CD3+, 
CD4+, CD8+) were determined by flow cytometry.Oncotarget 2012; 3:  22 - 30 28 www.impactjournals.com/oncotarget
gamma-globulin levels. Loss of regulatory B cells and 
concomitant augmented T cell immunity, however, may 
contribute to but are unlikely to be entirely responsible 
for the effect since tumor shrinkage was observed before 
decline in blood B cell counts. B cell lymphopenia as a 
side effect of targeting CD20+ melanoma cells did not 
produce recurrent infections in the patient and we expect 
B cell repopulation after discontinuation of treatment as 
known in rituximab lymphoma therapy [12]. 
Melanoma regression is likely accompanied by 
a concerted action of various anti-tumor mechanisms 
including a cellular immune response and vascular re-
modeling. The assumption is sustained by our observation 
that serum cytokine levels changed from a pronounced 
TH2 signature before rituximab therapy to a more pro-
inflammatory TH1 signature with a nearly 8fold increase 
in IFN-γ and TNF-α levels indicating a strong induction 
of an adaptive immune cell response. Concomitantly, the 
functional activity of CD4+ helper T cells was improved 
indicated by increased serum levels of IL-1β, IL-9, IL-
10 and eotaxin. We did not observe, however, auto-
immune destruction of melanocytes resulting in vitilgo 
which is thought to be a side effect of anti-melanoma 
T cell response and is now discussed to play a role in 
supporting T cell responses to melanoma (13). Increased 
IL-12, on the other hand, contributes to boost the innate 
immune response while the increase of the anti-angiogenic 
factor CXCL10 together with a decreased VEGF 
level counteracts neo-angiogenesis and thereby likely 
contributes to the observed shrinkage of the melanoma 
lesions.  
The therapeutic effect, however, is unlikely due to 
the concomitant dacarbazine therapy since melanoma 
lesions continuously progressed for 3 months during 
that treatment while stopped progression and turned into 
regression after the rituximab administration. Low dose 
dacarbazine treatment, however, may potentiate the effects 
of rituximab to some extent, for instance by sensitizing 
tumor cells which would otherwise survive therapy. 
Whether this or other pre-treatment regimens would 
further increase the anti-melanoma activity of rituximab 
remains to be resolved. 
Whereas the cancer stem cell concept has thus 
far been based on pre-clinical models, the present data 
provide the first clinical evidence for a hierarchical tumor 
cell organization in an established melanoma lesion, 
in particular the predominance of CD20+ melanoma 
cells as the “master cell” required for maintaining and 
promoting an established melanoma lesion. The crucial 
feature of the therapeutic approach is that the minority 
of CD20+ melanoma cells needs to be therapeutically 
targeted to produce regression of the melanoma lesion 
as a whole. Recent data from our group [9] based on a 
pre-clinical transplantation mouse model provide strong 
evidence that T cell targeted elimination of the minority 
of CD20+ melanoma cells prohibit melanoma progression 
resulting in the eradication of the disease whereas the 
mass of cancer cells is not therapeutically targeted. 
Moreover, mathematical models which simulate the effect 
of targeting different tumor subset cells [8] support our 
observation that elimination of tumor-maintaining “master 
cells” is both required and sufficient to induce tumor 
regression, whereas increase in the death rate or decrease 
in the production of mature tumor cells may be auxiliary 
but inadequate to eradicate progressively growing 
cancer lesions when used alone. The delayed onset of 
tumor shrinkage after rituximab therapy is expected in 
this context. These models, however, do so far not take 
the plasticity of cancer cells into account, meaning that 
differentiated tumor stem cells may acquire stem cell 
properties when gaining access to the stem cell niche 
(14). Consequently, anti-stem cell therapy needs to be 
repetitively applied to eliminate those reverting cells and 
provides the rationale to administer rituximab repetitively 
over a longer period of time in our patient.
The same melanoma subset cells may be targeted by 
other therapeutic anti-CD20 antibodies like ofatumumab 
or the next generation antibody GA-101 which possibly 
show more potent in the therapy of chronic lymphocytic 
leukemia  (15).  Instead  of  antibodies,  CD20-specific 
cytolytic T cells can be adoptively transferred which were 
engineered by expression of a recombinant T cell receptor 
or a chimeric antigen receptor; the latter was recently 
explored in a pre-clinical model [9]. Unlike cell-based 
therapies, antibody-mediated therapy has the benefit that 
antibody doses can be controlled in serum levels and are 
cleared with a defined half-life which is crucial in case 
of adverse events. Drug discovery approaches to target 
crucial signaling pathways in cancer stem cells including 
the Notch, Hedgehog and Wnt signaling pathway are 
currently explored at various levels (16). Complete 
response of chemotherapy-resistant melanoma highlights 
the potency of selectively eliminating tumor sustaining 
cells and warrants exploration of a greater patient cohort.
MATERIALS AND METHODS
General laboratory statement
Research sample processing, freezing, and laboratory 
analyses were performed in the CIO Studies Laboratory at 
the University Hospital of Cologne which operates under 
principles of Good Laboratory Practice with established 
SOP’s and/or protocols for sample receipt, processing, 
freezing, and analysis. 
Immunohistochemical staining of biopsies
A cutaneous metastasis of the heel was excised in 
total, shock-frozen in liquid nitrogen, embedded in Tissue Oncotarget 2012; 3:  22 - 30 29 www.impactjournals.com/oncotarget
Tek® Cryomolds™ containing O.C.T.™ compound 
(Sakura Finetek, Zoeterwoude, The Netherlands) and 
stored at -80 °C. Cryostat microtome 5 µm sections 
were fixed in ice-cold acetone and re-hydrated in PBS. 
Endogenous peroxidase activity was blocked with 
3% (v/v) H2O2 for 10 minutes followed by blocking of 
unspecific binding sites with 10% (v/v) goat serum for 
30 minutes. Slides were incubated with the monoclonal 
mouse anti-human CD20 antibody L26 (Abcam, 
Cambridge, UK) (5 µg/ml) for 1 hour, washed thrice in 
PBS and incubated with the horse radish peroxidase-
conjugated goat anti-mouse-IgG antibody sc2005 (Santa 
Cruz Biotechnology, Santa Cruz, CA) (5 µg/ml) for 1 
hour at room temperature. Incubation with a secondary 
antibody of irrelevant specificity served as isotype control. 
Labeled cells were detected by AEC substrate; cells were 
counterstained with hematoxylin. 
Serum cytokines
The concentration of a panel of 27 cytokines and 
chemokines in patient sera was determined using the 
“Bio-Plex Pro Human Cytokine 27-Plex Panel” (Bio-Rad, 
Munich, Germany) and the “Luminex Reader” according 
to the manufacturer’s instructions.
Study procedures
Cutaneous melanoma metastases on the lateral part 
of the left ankle, subcutaneous metastases in the left 
dorsal popliteal region and in the left inguinal region 
were treated by intra-lesional rituximab injections 
(10 mg in 4 ml NaCl 0.9%). Treated areas were first 
disinfected and anesthetized with a 2% (v/v) xylocaine 
injection. Rituximab doses and the treatment schedule are 
summarized in Table 1. No treatment related side effects 
occurred. Ongoing i.v. dacarbazine (1 g/m2 in 1L NaCl 
0.9%) treatment was repeated at monthly intervals. Pre-
medication was performed with granisetron (1 mg) and 
dexamethason (4 mg). Blood and serum samples were 
analyzed in the accredited Central Laboratory at the 
University Hospital Cologne.
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